Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
Nanobiotix S.A. - ADSs (NBTX)
Company Research
Source: GlobeNewswire
PARIS and CAMBRIDGE, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced achievement of operational requirements in NANORAY-312, an ongoing pivotal Phase 3 study evaluating potential first-in-class radioenhancer NBTXR3 for elderly patients with head and neck cancer, resulting in a $20M milestone payment from strategic partner Janssen Pharmaceutica NV (“Janssen”), a Johnson & Johnson company. “This first milestone payment related to our ongoing pivotal Phase 3 study evaluating NBTXR3 for patients with head and neck cancer represents another step forward in our pathway to bring NBTXR3 to registration,” said Laurent Levy, Nanobiotix co-founder and chairman of the executive board. “We look forward to continued collaboration with Janssen as we work to deliver the potential benefits
Show less
Read more
Impact Snapshot
Event Time:
NBTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBTX alerts
High impacting Nanobiotix S.A. - ADSs news events
Weekly update
A roundup of the hottest topics
NBTX
News
- Nanobiotix S.A. (NASDAQ: NBTX) had its "buy" rating re-affirmed by analysts at HC Wainwright.MarketBeat
- Nanobiotix reports FY results [Seeking Alpha]Seeking Alpha
- NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial ResultsGlobeNewswire
- NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024GlobeNewswire
NBTX
Analyst Actions
- 4/30/24 - HC Wainwright
NBTX
Sec Filings
- 4/24/24 - Form 6-K
- 4/24/24 - Form 20-F
- 4/17/24 - Form 6-K
- NBTX's page on the SEC website